Find syndicated market insights and custom brand analyses through our services offered in the nephrology market. Spherix’s independent research is conducted by our intelligence teams in collaboration with our proprietary network of nephrologists, patients, and leading KOLs.
According to Spherix Global Insights, nephrologists overwhelmingly chose the DAPA-CKD trial as the most compelling among the eight presented during...
Though surveyed US specialists report shrinking trepidation prescribing certain drugs amid the COVID-19 pandemic, hesitation to prescribe new brands remains...
The SGLT2 inhibitor class, specifically Janssen’s Invokana (promoted by Relypsa in nephrology), is gaining momentum with nephrologists as potential DKD...
According to Spherix Global Insights, nephrologists anxiously await pipeline products such as Retrophin’s sparsentan, Aurinia’s voclosporin, Reata’s bardoxolone methyl, and...
